Biocon partner secures ₹500 cr insulin supply contract
pre-market1 source ↓written by the desknot a recommendation
- insulin supply contract
- ₹515 cr
- human insulin worth
- ₹350 cr
- and aspart totaling
- ₹160 cr
Biocon's partner, Duopharma Biotech, has secured a ₹515 cr insulin supply contract from the Malaysian Ministry of Health. The agreement includes a three-year supply of human insulin worth ₹350 cr, plus two additional contracts for insulin glargine and aspart totaling ₹160 cr. This deal reinforces Biocon's strong presence in Malaysia's insulin market.
Not investment advice. For informational purposes only.